Research To Practice | Oncology Videos

Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics: Introduction (0:00) Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59) Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53) Other Novel Agents and Strategie...

Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers r...

Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surroundi...

Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen rec...

Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (25...

Featuring an interview with Dr Nikhil I Khushalani, including the following topics: Overview of nonmelanoma skin cancers (0:00) Systemic therapy for nonmelanoma skin cancers (12:11) Immune checkpoint inhibitors for special patient populations (20:30) Hedgehog inhibitors for basal cell carcinoma (32:14) New developments in therapy for nonmelanoma skin cancers (38:52) Case: A man in his early 70s wi...

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal...

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information a...

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics: Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00) Second-Line Treatment for Metastatic Breast Cancer (16:01) First-Line Therapy for Metastatic Disease (33:19) Adjuvant Therapy (35:26) Toxicity, Quality of Life (47:59) New Directions (55:22) CME information and select publicati...

Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics: Introduction: Genomics of EGFR (and HER2) (0:00) Metastatic Disease (9:30) Localized Disease (30:22) EGFR Exon 20 Insertion Mutations (46:57) New Agents (54:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) — Helena Yu, MD CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune chec...

Featuring perspectives from Dr Andrew J Armstrong and Dr Scott T Tagawa, including the following topics: Introduction: Evolution of the Prostate Cancer Model; Prostate Cancer Working Group 4 (PCWG4) (0:00) Hormonal Therapy (5:48) Chemotherapy (Docetaxel) (26:38) PARP Inhibition (29:49) Radioligand Therapy (36:56) New Agents (43:37) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Scott T Tagawa, MD, MS CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Andrew J Armstrong, MD, ScM CME information and select publications

Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications

Featuring an interview with Dr Natalie Vokes, including the following topics: Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00) Ohara S et al.  Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study.   JTO Clin Res Rep  2024;6(3):10076...

Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for th...

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) Ap...

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A woman in her early 60s with muscle-invasive bladder cancer experiences disease progression with lung metastasis after surgery and receives enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his mid 70s with metastatic urotheli...

Featuring perspectives from Dr Virginia F Borges and Dr Ian E Krop, including the following topics: Introduction: Biology of "Triple-Positive" Breast Cancer; Implications for Therapeutic Development (0:00) Cases from the GMO Survey (13:01) First-Line Therapy for Metastatic HER2-Positive Disease (20:01) Maintenance Therapy for HR-Positive, HER2-Positive Disease (30:03) Maintenance Therapy for HR-Ne...